Drugs with a negative impact on cognitive functions (Part 2): drug classes to consider while prescribing in CKD patients

Basit Öğe Kaydı
dc.contributor.authorHafez, Gaye
dc.contributor.authorMalyszko, Jolanta
dc.contributor.authorGolenia, Aleksandra
dc.contributor.authorKlimkowicz-Mrowiec, Aleksandra
dc.contributor.authorFerreira, Ana Carina
dc.contributor.authorArıcı, Mustafa
dc.contributor.authorBruchfeld, Annette
dc.contributor.authorNitsch, Dorothea
dc.contributor.authorMassy, Ziad A.
dc.contributor.authorPepin, Marion
dc.contributor.authorCapasso, Giovambattista
dc.contributor.authorMani, Laila-Yasmin
dc.contributor.authorLiabeuf, Sophie
dc.date.accessioned2023-11-07T12:34:27Z
dc.date.available2023-11-07T12:34:27Z
dc.date.issued2023en_US
dc.departmentFakülteler, Eczacılık Meslek Bilimleri Bölümü, Farmakoloji Ana Bilim Dalıen_US
dc.description.abstractThere is growing evidence that chronic kidney disease (CKD) is an independent risk factor for cognitive impairment, especially due to vascular damage, blood-brain barrier disruption and uremic toxins. Given the presence of multiple comorbidities, the medication regimen of CKD patients often becomes very complex. Several medications such as psychotropic agents, drugs with anticholinergic properties, GABAergic drugs, opioids, corticosteroids, antibiotics and others have been linked to negative effects on cognition. These drugs are frequently included in the treatment regimen of CKD patients. The first review of this series described how CKD could represent a risk factor for adverse drug reactions affecting the central nervous system. This second review will describe some of the most common medications associated with cognitive impairment (in the general population and in CKD) and describe their effects.en_US
dc.identifier.citationHafez, G., Malyszko, J., Golenia, A., Klimkowicz-Mrowiec, A., Ferreira, A. C., Arici, M., ... & Liabeuf, S. (2023). Drugs with a negative impact on cognitive functions (Part 2): drug classes to consider while prescribing in CKD patients. Clinical Kidney Journal.en_US
dc.identifier.issn2048-8505
dc.identifier.issn2048-8513
dc.identifier.scopus2-s2.0-85182906869
dc.identifier.scopusqualityN/A
dc.identifier.urihttps://hdl.handle.net/20.500.12939/4219
dc.identifier.wosWOS:001081414700001
dc.identifier.wosqualityQ1
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.institutionauthorHafez, Gaye
dc.language.isoen
dc.relation.ispartofClinical Kidney Journal
dc.relation.isversionof10.1093/ckj/sfad239en_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectAdverse drug reactionsen_US
dc.subjectChronic kidney diseaseen_US
dc.subjectCognitive impairmenten_US
dc.subjectDrug prescriptionen_US
dc.subjectMedicationsen_US
dc.titleDrugs with a negative impact on cognitive functions (Part 2): drug classes to consider while prescribing in CKD patients
dc.typeReview Article

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim
İsim:
sfad239 (1).pdf
Boyut:
1.06 MB
Biçim:
Adobe Portable Document Format
Açıklama:
Tam Metin / Full Text
İndir
Lisans paketi
Listeleniyor 1 - 1 / 1
[ X ]
İsim:
license.txt
Boyut:
1.44 KB
Biçim:
Item-specific license agreed upon to submission
Açıklama:
İndir

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
Eczacılık Fakültesi Yayın Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu